The global HIV drugs market is projected to grow from 27 billion dollars in 2019 to 34.2 billion dollars in 2023 with an estimated compound annual growth rate of 5.9%. (1) The most important driver for the expansion of the HIV drug market is the increase in awareness of prevention and available treatments of HIV that are raised by various non-profit organizations as well as government agencies among the global community. By drug class, these therapeutics are categorized into combination HIV drugs, integrase inhibitors, antiretroviral drugs, and non-nucleoside reverse transcriptase inhibitors (NRTIs), etc. (2) Out of these, NRTIs afforded 5.6% of the overall market, which showed a drastically reduced demand for this drug class.
Furthermore, major pharmaceutical companies in the HIV drugs market are primarily researching on implementing multi-class combination products for the antiretroviral therapies (ART) in order to maintain their market shares. ART drugs work by helping to reduce viral load, stopping the virus from replicating in the body, boosting the body’s immune system to combat viral infections, and preventing HIV transmission in communities. (1) Unfortunately, the short-term and long-term adverse side effects remain the biggest challenge in ART pharmaceuticals. These side effects associated with the therapy include diarrhea, headache, fatigue, depression, muscle pain, and heart disease, which can potentially impact the growth of the HIV therapeutics market.
References
HIV Drugs Market Worth $30.5 Billion in 2020 due to the Increase in Demand of HIV Drugs for the Treatment of COVID-19 Patients - ResearchAndMarkets.com | Business Wire https://www.businesswire.com/news/home/20200505005791/en/HIV-Drugs-Market-Worth-30.5-Billion-in-2020-due-to-the-Increase-in-Demand-of-HIV-Drugs-for-the-Treatment-of-COVID-19-Patients---ResearchAndMarkets.com (accessed Feb 13, 2022).
HIV Drugs Market to Hit USD 45.58 Billion by 2028, With https://www.globenewswire.com/news-release/2021/06/29/2254516/0/en/HIV-Drugs-Market-to-Hit-USD-45-58-Billion-by-2028-With-5-9-CAGR-Emergence-of-Antiretroviral-Therapy-as-a-Long-acting-Suppression-to-Boost-Growth-says-Fortune-Business-Insights.html (accessed Feb 13, 2022).
Comments